Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas
AffiliationThe University of Arizona Cancer Center, 1515 N. Campbell Avenue, Tucson, AZ, USA
Department of Pathology, University of Arizona, Tucson, AZ, USA
MetadataShow full item record
CitationMorgan et al. Clinical Sarcoma Research 2014, 4:2 http://www.clinicalsarcomaresearch.com/content/4/1/2
JournalClinical Sarcoma Research
Rights© 2014 Morgan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0)
Collection InformationThis item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at firstname.lastname@example.org.
Abstractp=0.0016).CONCLUSIONS:SPARC expression is elevated in a significant proportion of STS specimens analyzed in this study, but it does not appear to correlate with specific STS histologies. Given our limited sample size, we cannot draw definitive conclusions regarding association of SPARC with STS subtype. Overall survival segregates strongly by degree of SPARC expression, with elevated expression being adverse. If validated in a larger study, our results suggest that trials in STS with agents potentially targeting SPARC, such as NAB-paclitaxel, should be stratified by SPARC expression level.
VersionFinal published version